葵花葯業(002737.SZ):擬使用1億元參與認購得怡投資基金的有限合夥份額
格隆匯7月6日丨葵花葯業(002737.SZ)公佈,公司於2021年7月6日召開公司第四屆董事會第八次會議,審議通過《關於參與認購基金份額的議案》,公司決定與得怡投資管理(北京)有限公司(“得怡投資”)、山東羅欣控股有限公司、成都光華開源資本管理有限責任公司、自然人陳明、李小強、胡蕾簽訂相關合夥協議,公司將使用自有資金1億元人民幣參與認購成都得怡欣華股權投資合夥企業(有限合夥)(“得怡投資基金”或“基金”)的有限合夥份額,基金上限為20億元人民幣(本輪募集結束後基金規模為65375萬元。其中,公司認繳1億元。)
基金的投資範圍:1.受讓某A 股上市公司的股權;2.大健康產業領域投資:生物製藥、化學制藥、中成藥、醫藥研發服務機構、醫療器械企業、醫藥相關AI 大數據及醫療服務等領域。
通過此次投資,可以在以下方面為公司戰略落地提供助力:1、藉助基金專業機構的專業投資團隊、強大的資源挖掘和整合能力,不斷完善公司在醫藥醫療等大健康領域的戰略佈局,構建大健康生態圈;2、同時基金也能夠為公司孵化研發管線,待成熟後與公司進行嫁接組合,豐富公司管線內容,提升公司盈利能力;3、基金的主要出資方羅欣藥業也深耕醫藥行業多年,通過本基金的鏈接,有可能促成羅欣藥業銷售團隊與葵花葯業銷售團隊強強聯合,優勢互補,進一步提升雙方在各自優勢領域的市場份額,互惠互利;4、基金通過向具有良好成長性和發展前景的項目進行投資,有利於提升公司資金的使用效率,提升公司的盈利水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.